James Yu

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 9

Top Topics

Dna Methylation

Radical Prostatectomy

Prostate Cancer

Top Venues

OncoTargets and therapy

Journal of hepatocellular carcinoma

This page only lists publications with an associated author ORCID identifier.

Publications

Dae Won Kim, Young-Chul Kim, Bence P Kovari, Maria Martinez, Ruoyu Miao, James Yu, Rutika Mehta, Jonathan R Strosberg, Iman Imanirad, Richard D Kim
Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer. Cancers 16 (3) (2024)
Turab Mohammed, James Yu, Yong Qiao, Youngchul Kim, Eric M Mortensen, Helen Swede, Zhao Wu, Jingsong Zhang
Marijuana Use May Be Associated with Reduced Prevalence of Prostate Cancer: A National Survey on Drug Use and Health Study from United States of America. Biomedicines 12 (5) (2024)
Alireza Tojjari, James Yu, Anwaar Saeed
Immunotherapy and Radiation Therapy Combinatorial Approaches in Hepatocellular Carcinoma. Cancers 16 (5) (2024)
Alireza Tojjari, James Yu, Anwaar Saeed
Immunotherapy and Radiation Therapy Combinatorial Approaches in Hepatocellular Carcinoma. Cancers 16 (5) (2024)
Dae Won Kim, Young-Chul Kim, Bence P Kovari, Maria Martinez, Ruoyu Miao, James Yu, Rutika Mehta, Jonathan R Strosberg, Iman Imanirad, Richard D Kim
Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer. Cancers 16 (3) (2024)
Turab Mohammed, James Yu, Yong Qiao, Youngchul Kim, Eric M Mortensen, Helen Swede, Zhao Wu, Jingsong Zhang
Marijuana Use May Be Associated with Reduced Prevalence of Prostate Cancer: A National Survey on Drug Use and Health Study from United States of America. Biomedicines 12 (5) (2024)
James Yu, Robin Park, Richard Kim
Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights. Journal of hepatocellular carcinoma 10 (2023)
James Yu, Amit Mahipal, Richard Kim
Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib. OncoTargets and therapy 14 (2021)
James Yu, Jingxin Sun, Yuan Du, Rushang Patel, Juan Carlos Varela, Shahram Mori, Chung-Che Chang
Adverse Impact of DNA Methylation Regulatory Gene Mutations on the Prognosis of AML Patients in the 2017 ELN Favorable Risk Group, Particularly Those Defined by NPM1 Mutation. Diagnostics (Basel, Switzerland) 11 (6) (2021)